RAC2 (Gene)

Organism:

Homo sapiens

Synonyms:EN-7, ENTREZ:5880, Gx, HGNC:9802, HSPC022, IMD73A, IMD73B, IMD73C, MIM:602049, NM_002872, NP_002863, RAC2, Rac family small GTPase 2, XM_006724286, XP_006724349, p21-Rac2

Omim:OMIM:602049

Id:ENSG00000128340

Hgnc:HGNC:9802

Entrez:5880

Ensembl:ENSG00000128340

Description:Rac family small GTPase 2

This gene encodes a member of the Ras superfamily of small guanosine triphosphate (GTP)-metabolizing proteins. The encoded protein localizes to the plasma membrane, where it regulates diverse processes, such as secretion, phagocytosis, and cell polarization. Activity of this protein is also involved in the generation of reactive oxygen species. Mutations in this gene are associated with neutrophil immunodeficiency syndrome. There is a pseudogene for this gene on chromosome 6. [provided by RefSeq, Jul 2013]

Analyze

CFDE DD-Knowledge Graph

The CFDE Data Distillery Knowledge Graph contains entities and relationships across the CFDE. View RAC2's neighborhood in the knowledge graph.

Submit

Playbook Workflow Builder: Gene-Centric Workflow

View Gene-Centric information about the gene from a pre-built PWB workflow. View the workflow with RAC2.

CFDE Gene-Centric Appyter

The CFDE Gene Centric Appyter Resolves and Displays Gene-Centric information from CFDE APIs. Execute the Appyter using RAC2.

Submit

GDLPA Landing Pages Links

The Gene and Drug Landing Page Aggregator (GDLPA) finds links to primary and secondary source information from CFDE and other resources. Discover landing pages for RAC2.

Submit

Playbook Workflow Builder

The Playbook Workflow Builder helps you interactively construct workflows leveraging CFDE APIs without code. Start a new workflow with RAC2.

Results found

Linked to

	Label	Description
	GSE240439 decitabine 1 v 2 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE135350 2 V 4 DEXAMETHASONE HUMAN DN Gene Set (Entity type)	A Gene Set from LINCS
	GSE199688 artemisinin 0 v 1 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE144443 0 V 6 NICOTINAMIDE MOUSE UP Gene Set (Entity type)	A Gene Set from LINCS
	GSE172016 2 V 5 PACLITAXEL HUMAN UP Gene Set (Entity type)	A Gene Set from LINCS
	GSE110178 2 V 3 TRANYLCYPROMINE MOUSE DN Gene Set (Entity type)	A Gene Set from LINCS
	GSE114492 GSE153671 KMT2D inhibition 6 v 8 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE199107 tryptophan 6 v 7 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE195568 palbociclib 2 v 10 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE48812 sulforaphane 4 v 10 human dn Gene Set (Entity type)	A Gene Set from LINCS

GSE240439 decitabine 1 v 2 human up

Gene Set (Entity type)

A Gene Set from LINCS

GSE135350 2 V 4 DEXAMETHASONE HUMAN DN

Gene Set (Entity type)

A Gene Set from LINCS

GSE199688 artemisinin 0 v 1 human dn

Gene Set (Entity type)

A Gene Set from LINCS

GSE144443 0 V 6 NICOTINAMIDE MOUSE UP

Gene Set (Entity type)

A Gene Set from LINCS

GSE172016 2 V 5 PACLITAXEL HUMAN UP

Gene Set (Entity type)

A Gene Set from LINCS

GSE110178 2 V 3 TRANYLCYPROMINE MOUSE DN

Gene Set (Entity type)

A Gene Set from LINCS

GSE114492 GSE153671 KMT2D inhibition 6 v 8 human up

Gene Set (Entity type)

A Gene Set from LINCS

GSE199107 tryptophan 6 v 7 human up

Gene Set (Entity type)

A Gene Set from LINCS

GSE195568 palbociclib 2 v 10 human up

Gene Set (Entity type)

A Gene Set from LINCS

GSE48812 sulforaphane 4 v 10 human dn

Gene Set (Entity type)

A Gene Set from LINCS

DISPLAY PER PAGE

CFDE Workbench

Consortium

Community

Resources

@CFDE Workbench 2026

The CFDE Workbench is actively being developed and maintained by the CFDE Data Resource Center (DRC).The DRC is funded by OT2OD036435 from the Common Fund at the National Institutes of Health.

Consortium

Community

Resources

CFDE Workbench

The CFDE Workbench is actively being developed and maintained by the CFDE Data Resource Center (DRC).The DRC is funded by OT2OD036435 from the Common Fund at the National Institutes of Health.

@CFDE Workbench 2026

This repository is under review for potential modification in compliance with Administration directives.